Suppr超能文献

遗传性乳腺癌高危女性的迟发性乳腺癌风险。

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

机构信息

Mayo Clinic, Rochester, MN.

Beckman Research Institute of City of Hope, Duarte, CA.

出版信息

J Clin Oncol. 2021 Nov 1;39(31):3430-3440. doi: 10.1200/JCO.21.00531. Epub 2021 Jul 22.

Abstract

PURPOSE

The prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have < 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years.

METHODS

A total of 26,707 women over age 65 years from population-based studies (51.5% with breast cancer and 48.5% unaffected) were tested for PVs in germline predisposition gene. Frequencies of PVs and associations between PVs in each gene and breast cancer were assessed, and remaining lifetime breast cancer risks were estimated for non-Hispanic White women with PVs.

RESULTS

The frequency of PVs in predisposition genes was 3.18% for women with breast cancer and 1.48% for unaffected women over age 65 years. PVs in , , and were found in 3.42% of women diagnosed with estrogen receptor (ER)-negative, 1.0% with ER-positive, and 3.01% with triple-negative breast cancer. Frequencies of PVs were lower among women with no first-degree relatives with breast cancer. PVs in , , , and were associated with increased risks (odds ratio = 2.9-4.0) of breast cancer. Remaining lifetime risks of breast cancer were ≥ 15% for those with PVs in , , and .

CONCLUSION

This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with and PVs and perhaps with and PVs should be considered for magnetic resonance imaging screening.

摘要

目的

在 65 岁以上的普通人群中,已确立的乳腺癌易感基因中的种系致病性变异(PV)的流行率尚不清楚。然而,检测指南表明,65 岁以上被诊断患有乳腺癌的女性在高外显率基因中出现 PV 的可能性<2.5%。本研究旨在确定 65 岁以上女性中每个基因的 PV 频率和乳腺癌的剩余风险。

方法

共有 26707 名来自基于人群的研究的 65 岁以上女性(51.5%患有乳腺癌,48.5%未受影响)接受了种系易感性基因中 PV 的检测。评估了每个基因中的 PV 频率以及与乳腺癌的关联,并为具有 PV 的非西班牙裔白人女性估计了剩余的终身乳腺癌风险。

结果

乳腺癌患者中易患基因的 PV 频率为 3.18%,65 岁以上未受影响的女性为 1.48%。在诊断为雌激素受体(ER)阴性、ER 阳性和三阴性乳腺癌的女性中,分别有 3.42%、1.0%和 3.01%发现了 、 和 的 PV。没有一级亲属患有乳腺癌的女性中,PV 的频率较低。 、 、 和 的 PV 与乳腺癌风险增加相关(比值比=2.9-4.0)。具有 、 、 和 的 PV 的女性的乳腺癌剩余终生风险≥15%。

结论

本研究表明,所有诊断为三阴性乳腺癌或 ER 阴性乳腺癌的女性均应接受基因检测,65 岁以上且具有 、 或 、 和 的 PV 的女性应考虑进行磁共振成像筛查。

相似文献

1
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
J Clin Oncol. 2021 Nov 1;39(31):3430-3440. doi: 10.1200/JCO.21.00531. Epub 2021 Jul 22.
2
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in , , , , and .
J Clin Oncol. 2023 Mar 20;41(9):1703-1713. doi: 10.1200/JCO.22.01239. Epub 2023 Jan 9.
6
Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Breast Cancer Res Treat. 2020 Jun;181(2):465-473. doi: 10.1007/s10549-020-05643-0. Epub 2020 Apr 21.
7
Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
Ann Oncol. 2024 Oct;35(10):892-901. doi: 10.1016/j.annonc.2024.07.244. Epub 2024 Jul 8.
8
Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
J Clin Oncol. 2021 Dec 10;39(35):3918-3926. doi: 10.1200/JCO.21.00640. Epub 2021 Oct 21.

引用本文的文献

1
Genomic landscape of breast cancer in elderly patients.
NPJ Breast Cancer. 2025 Jul 10;11(1):70. doi: 10.1038/s41523-025-00781-4.
2
Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer.
JAMA Netw Open. 2024 Dec 2;7(12):e2452158. doi: 10.1001/jamanetworkopen.2024.52158.
3
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.
Clin Cancer Res. 2025 Jan 6;31(1):130-138. doi: 10.1158/1078-0432.CCR-24-1884.
4
Current status and challenges in HER2 IHC assessment: scoring survey results in Japan.
Breast Cancer Res Treat. 2025 Feb;210(1):27-36. doi: 10.1007/s10549-024-07532-2. Epub 2024 Nov 4.
6
Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System.
Ann Surg Oncol. 2025 Jan;32(1):75-83. doi: 10.1245/s10434-024-16223-7. Epub 2024 Sep 18.
8
Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.
Breast Cancer Res Treat. 2024 Jun;205(2):281-285. doi: 10.1007/s10549-023-07234-1. Epub 2024 Feb 21.
9
Hereditary cancer testing in a diverse sample across three breast imaging centers.
Breast Cancer Res Treat. 2024 Jan;203(2):365-372. doi: 10.1007/s10549-023-07137-1. Epub 2023 Oct 20.

本文引用的文献

1
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
J Clin Oncol. 2021 Aug 10;39(23):2564-2573. doi: 10.1200/JCO.20.01992. Epub 2021 Jun 8.
2
A Population-Based Study of Genes Previously Implicated in Breast Cancer.
N Engl J Med. 2021 Feb 4;384(5):440-451. doi: 10.1056/NEJMoa2005936. Epub 2021 Jan 20.
3
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.
4
Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk.
JCO Precis Oncol. 2020 Jun 8;4. doi: 10.1200/PO.19.00360. eCollection 2020.
5
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.
6
Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
J Natl Cancer Inst. 2020 Dec 14;112(12):1213-1221. doi: 10.1093/jnci/djaa040.
7
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. doi: 10.6004/jnccn.2020.0017.
10
MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer.
Genet Med. 2018 Oct;20(10):1167-1174. doi: 10.1038/gim.2017.254. Epub 2018 Jan 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验